These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12959626)

  • 21. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications.
    Dams J; Balzer-Geldsetzer M; Siebert U; Deuschl G; Schuepbach WM; Krack P; Timmermann L; Schnitzler A; Reese JP; Dodel R;
    Mov Disord; 2016 Aug; 31(8):1183-91. PubMed ID: 27506638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment benefit and daily drug costs associated with treating Parkinson's disease in a Parkinson's disease clinic.
    Müller T; Voss B; Hellwig K; Josef Stein F; Schulte T; Przuntek H
    CNS Drugs; 2004; 18(2):105-11. PubMed ID: 14728057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Costs of illness and care in Parkinson's disease: an evaluation in six countries.
    von Campenhausen S; Winter Y; Rodrigues e Silva A; Sampaio C; Ruzicka E; Barone P; Poewe W; Guekht A; Mateus C; Pfeiffer KP; Berger K; Skoupa J; Bötzel K; Geiger-Gritsch S; Siebert U; Balzer-Geldsetzer M; Oertel WH; Dodel R; Reese JP
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):180-91. PubMed ID: 20888737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of pramipexole in Parkinson's disease in the US.
    Hoerger TJ; Bala MV; Rowland C; Greer M; Chrischilles EA; Holloway RG
    Pharmacoeconomics; 1998 Nov; 14(5):541-57. PubMed ID: 10344917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
    Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
    J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
    Iskedjian M; Einarson TR
    Pharmacoeconomics; 2003; 21(2):115-27. PubMed ID: 12515573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs.
    Charles PD; Padaliya BB; Newman WJ; Gill CE; Covington CD; Fang JY; So SA; Tramontana MG; Konrad PE; Davis TL
    Parkinsonism Relat Disord; 2004 Dec; 10(8):475-9. PubMed ID: 15542007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
    Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
    Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bridging decision analytic modelling with a cross-sectional study. Application to Parkinson's disease.
    Nuijten MJ
    Pharmacoeconomics; 2000 Mar; 17(3):227-36. PubMed ID: 10947298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost analysis of unilateral and bilateral pallidotomy for Parkinson's disease.
    Green AL; Joint C; Sethi H; Bain P; Aziz TZ
    J Clin Neurosci; 2004 Nov; 11(8):829-34. PubMed ID: 15519857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Parkinson's disease: cost-of-illness in an outpatient cohort].
    Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
    Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating the direct and indirect costs associated with Parkinson's disease.
    Rodríguez-Blázquez C; Forjaz MJ; Lizán L; Paz S; Martínez-Martín P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):889-911. PubMed ID: 26511768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An economic model of Parkinson's disease: implications for slowing progression in the United States.
    Johnson SJ; Diener MD; Kaltenboeck A; Birnbaum HG; Siderowf AD
    Mov Disord; 2013 Mar; 28(3):319-26. PubMed ID: 23404374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pimavanserin (Nuplazid) for Parkinson's disease psychosis.
    Med Lett Drugs Ther; 2016 Jun; 58(1496):74-5. PubMed ID: 27249096
    [No Abstract]   [Full Text] [Related]  

  • 36. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan.
    Shimbo T; Hira K; Takemura M; Fukui T
    Pharmacoeconomics; 2001; 19(8):875-86. PubMed ID: 11596839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
    Watkins JB; Minshall ME; Sullivan SD
    J Manag Care Pharm; 2006; 12(9):726-35. PubMed ID: 17249905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring sensitivity in pharmacoeconomic studies. Refining point sensitivity and range sensitivity by incorporating probability distributions.
    Nuijten MJ
    Pharmacoeconomics; 1999 Jul; 16(1):33-41. PubMed ID: 10539120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic benefit to society at large of total knee arthroplasty in younger patients: a Markov analysis.
    Bedair H; Cha TD; Hansen VJ
    J Bone Joint Surg Am; 2014 Jan; 96(2):119-26. PubMed ID: 24430411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug costs for patients with Parkinson's disease in two different European countries.
    Vossius C; Gjerstad M; Baas H; Larsen JP
    Acta Neurol Scand; 2006 Apr; 113(4):228-32. PubMed ID: 16542161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.